Fundraising Fox

Barinthusbio

NASDAQ: BRNS

4 known investors

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific immunotherapies designed to guide T cells to treat autoimmune and inflammatory diseases. The company was formed from the 2021 merger of Vaccitech (an Oxford University spinout) and Avidea Technologies (a spinout from NIH and Johns Hopkins University).

BiotechHealthtechMedical Devices

Founders & leadership

WE
William EnrightChief Executive Officer & Board Director
GL
Geoffrey LynnChief Scientific Officer
LH
Leon HooftmanChief Medical Officer

Investors · 4

Oxford Science EnterprisesOxford · $63.5K – $31.8M
GV (Google Ventures)reportedMountain View · $250K – $50M
Milltrust International GroupreportedLondon · $2.5M
XfundreportedPalo Alto · $50K – $500K

Frequently asked questions

What does Barinthusbio do?
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific immunotherapies designed to guide T cells to treat autoimmune and inflammatory diseases. The company was formed from the 2021 merger of Vaccitech (an Oxford University spinout) and Avidea Technologies (a spinout from NIH and Johns Hopkins University).
Who are Barinthusbio's investors?
Barinthusbio's investors include Oxford Science Enterprises, GV (Google Ventures), Milltrust International Group, Xfund.